<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949674</url>
  </required_header>
  <id_info>
    <org_study_id>R-2016-3401-55</org_study_id>
    <nct_id>NCT02949674</nct_id>
  </id_info>
  <brief_title>Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients</brief_title>
  <official_title>Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Mexicano del Seguro Social</source>
  <brief_summary>
    <textblock>
      Title: Ropivacaine versus Bupivacaine as Preventive Analgesia in Surgical Incision Site In
      Patients With Ankle Fracture Background: Ankle fractures are about 10% of the fractures
      associate to sports and with an incidence of 0.11 of 1000 adult patients. Weber
      classification system divides ankle fractures in three types according to the anatomy of
      lateral malleolus. B fractures starts at tibia pilon. Stable fractures are easily treated in
      conservative way. (12) Unstable fractures are treated surgically with anatomic reduction and
      internal fixation. However, it's been reported that even with successful reduction surgically
      great results are not always achieved. Local wound infiltration blocks the pain in its
      origin, surgical site by itself, without alter motor function. Practically without presenting
      adverse events with this method. itÂ´s accurate for ambulatory surgery.

      Main Objetive: To compare preventive analgesia with local anesthetic in surgical site with
      ropivacaine or bupivacaine in ankle fracture patients treated surgically with open reduction
      and internal fixation.

      Method: Two groups with ankle fractures which will be informed and the patients will sign
      informed consent, after that the patients will be assign to a group (Ropivacaine or
      bupivacaine). The patient will be prepared for surgical treatment according to his doctor. It
      will be applied traditional anesthesia. It will be applied before beginning surgery in
      bupivacaine group 25 mg and in ropivacaine group 37.5 mg at least 10 minutes before starting
      surgery. After that the patient will have the traditional dose of analgesic treatment.The
      group will evaluate the pain with VAS 0-10 at 4,8,12 and 24 hours after surgery. The group
      will register data and will make statistic analysis. It will be elaborated the conclusion an
      elaboration of a report.

      Resources: The group counts with human resources of the group of investigators. The hospital
      has in emergency department almost three patients with ankle fractures each day which require
      surgical treatment. The hospital has x ray service to valuate the ankle fracture and with
      computer system to analyze it. The hospital has the software for statistical analysis.

      Experience: The group is formed with orthopedic surgeons with more than 5 years in treatment
      of ankle fractures. Investigators have the support of pain medicine group in hospital and
      with anesthesia coordinators. Investigators have a group of orthopedic residents which will
      be encharged of ilfiltration wound site.

      Time: September 2016 to February 2017.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS</measure>
    <time_frame>Change in Visual Analogue Scale at 24 hours</time_frame>
    <description>The Pain will be measured with this scale from 0 (No pain) -10 (Worst pain possible) according to the investigator at 24 hours after surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Ankle Fractures</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Local Infiltration</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No application of anesthetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>It will be used as a analgesic dose in surgical site before surgery.</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>It will be used as a analgesic dose in surgical site before surgery.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>Bupivacaine hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with afiliation to IMSS

          -  Patient with ankle fracture that requires surgical treatment with open reduction and
             internal fixation

          -  Patient that accept to participate in the study whit a sign of document.

        Exclusion Criteria:

          -  Politrauma patients (Patients with another fracture)

          -  Patients who dont accept to participate in the study

          -  Neuropathy in inferior limps that limits pain perception

          -  Open ankle fractures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Jonathan De La Cruz Pacheco</last_name>
    <role>Study Chair</role>
    <affiliation>IMSS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMAE Dr. Victorio de La Fuente Narvaez</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>07020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <results_first_submitted>September 16, 2017</results_first_submitted>
  <results_first_submitted_qc>July 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2018</results_first_posted>
  <last_update_submitted>July 1, 2018</last_update_submitted>
  <last_update_submitted_qc>July 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Mexicano del Seguro Social</investigator_affiliation>
    <investigator_full_name>JUAN LOPEZ VALENCIA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Ankle Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment dates: January 2017 to April 2017, at High Specialty Unit Dr. Victorio de la Fuente Narvaez, IMSS</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine</title>
          <description>It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
Bupivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaine</title>
          <description>It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
Ropivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>No application of anesthetic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine</title>
          <description>It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
Bupivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaine</title>
          <description>It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
Ropivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>No application of anesthetic</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B2" value="37.16" lower_limit="18" upper_limit="71"/>
                    <measurement group_id="B3" value="33.71" lower_limit="18" upper_limit="67"/>
                    <measurement group_id="B4" value="37.7" lower_limit="18" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="31"/>
                    <count group_id="B4" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VAS</title>
        <description>The Pain will be measured with this scale from 0 (No pain) -10 (Worst pain possible) according to the investigator at 24 hours after surgery.</description>
        <time_frame>Change in Visual Analogue Scale at 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine</title>
            <description>It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
Bupivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine</title>
            <description>It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
Ropivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>No application of anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>VAS</title>
          <description>The Pain will be measured with this scale from 0 (No pain) -10 (Worst pain possible) according to the investigator at 24 hours after surgery.</description>
          <units>units on a scale (VAS)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VAS at 4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="1.302"/>
                    <measurement group_id="O2" value="2.13" spread="0.619"/>
                    <measurement group_id="O3" value="3.52" spread="1.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS at 8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.52" spread="1.022"/>
                    <measurement group_id="O2" value="3.04" spread="1.113"/>
                    <measurement group_id="O3" value="5.02" spread="0.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS at 12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="0.765"/>
                    <measurement group_id="O2" value="3.55" spread="0.995"/>
                    <measurement group_id="O3" value="4.84" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS at 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.03" spread="0.836"/>
                    <measurement group_id="O2" value="3.87" spread="0.783"/>
                    <measurement group_id="O3" value="4.10" spread="0.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine</title>
          <description>It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
Bupivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine</title>
          <description>It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
Ropivacaine: It will be used as a analgesic dose in surgical site before surgery.</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>No application of anesthetic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We consider that we can had a better result with higher dosis of local anesthetic, and the comparation with a placebo group would be a better analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Juan Lopez</name_or_title>
      <organization>Instituto Mexicano del Seguro Social</organization>
      <phone>+5257473500 ext 25538</phone>
      <email>juanlopez110@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

